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Abstract
The development of heme oxygenase (HO) inhibitors is critical in dissecting and understanding the HO system and for
potential therapeutic applications. We have established a program to design and optimize HO inhibitors using structure-
activity relationships in conjunction with X-ray crystallographic analyses. One of our previous complex crystal structures
revealed a putative secondary hydrophobic binding pocket which could be exploited for a new design strategy by
introducing a functional group that would fit into this potential site. To test this hypothesis and gain further insights into
the structural basis of inhibitor binding, we have synthesized and characterized 1-(1H-imidazol-1-yl)-4,4-diphenyl-2-
butanone (QC-308). Using a carbon monoxide (CO) formation assay on rat spleen microsomes, the compound was found to
be ,15 times more potent (IC50=0.2760.07 mM) than its monophenyl analogue, which is already a potent compound in its
own right (QC-65;I C 50=4.061.8 mM). The crystal structure of hHO-1 with QC-308 revealed that the second phenyl group in
the western region of the compound is indeed accommodated by a definitive secondary proximal hydrophobic pocket.
Thus, the two phenyl moieties are each stabilized by distinct hydrophobic pockets. This ‘‘double-clamp’’ binding offers
additional inhibitor stabilization and provides a new route for improvement of human heme oxygenase inhibitors.
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Introduction
The heme oxygenase (HO) system comprises two active
isozymes (HO-1 and HO-2) which are involved in the regioselec-
tive, oxidative cleavage of heme at the a-meso carbon. Cleavage
results in the release of equimolar amounts of the gasotransmitter
carbon monoxide (CO), ferrous iron (Fe
2+), and biliverdin, the
latter of which is reduced further by biliverdin reductase to form
bilirubin [1–3] (Figure 1). A third isozyme, HO-3, has been
deemed inactive despite exhibiting ,90% sequence identity with
HO-2 [4]. Of the two active isozymes, HO-1 is a ,32 kDa stress
protein found to be predominantly expressed in the spleen and
inducible by a variety of stimuli including heat shock, heavy
metals, heme and reactive oxygen species (ROS). The constitutive
HO-2, a ,36.5-kDa protein, is widely distributed with its highest
concentration in the brain and testes.
The HO reaction comprises ,85% of the CO produced in
humans under normal physiological conditions. CO has been
found to be one of the most important gasotransmitters in the
body, with evidence demonstrating regulatory involvement in anti-
inflammatory, antiapoptotic, antiproliferative and vasodilatory
effects [5–8]. Both biliverdin and bilirubin act to scavenge free
radicals such as superoxide, peroxyl radicals and peroxynitrite,
making them both powerful antioxidants [9–11]; indeed, bilirubin
has been shown to provide protection against oxidative stress-
induced pathologies [5]. In general, the HO system has
demonstrated a protective role against many diseases including
ischaemia-reperfusion injury and endotoxic shock, as well as
against graft rejection [12]. HO-1 has been found to do be
upregulated in several cancers, including pancreatic and prostate,
and in response to several anticancer treatments [13–15].
The development of isozyme-selective HO inhibitors should
provide powerful pharmacological tools in understanding the
HO/CO system, elucidating the mechanisms underlying its
physiological effects, as well as opening the door to potential
therapeutic applications. Historically, the major inhibitors used to
date have been the metalloporphyrins (e.g. tin/zinc/chromium
protoporphyrin) which act as competitive inhibitors due to their
structural similarity to the heme substrate. However, since heme is
essential for a number of biologically relevant enzymes, including
cytochrome P450, nitric oxide synthase (NOS) and soluble
guanylyl cyclase (sGC), the use of structural analogues to heme
is limited due to their lack of selectivity. Indeed, this has led to
some concerns about the interpretation of results and resultant
conclusions from previous studies of the HO/CO system [16–18].
It should be noted, however, that studies have also demonstrated
that some of these metalloporphyrins do maintain selectivity
against HO in vitro if used within a defined concentration range;
however, this is restricted to chromium mesoporphyrin IX at
concentrations up to 5 mM [19]. Thus, there is an obvious and
pressing need to develop isoselective HO inhibitors.
Our laboratoryhasbeen focused on a program aimed at the design
of novel, non-porphyrin based, isozyme-selective HO inhibitors
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[(1H-imidazol-1-yl)methyl]-4-[((4-aminophenyl)thio)methyl]-1,3-
dioxolane (azalanstat, Figure 2), which was discovered as a potent
and selective inhibitor of HO [20]. This program has resulted in the
discovery of several novel, azole-based compounds, deemed QC-
xx, which selectively and non-competitively inhibit HO without
affecting NOS or sGC, except at high millimolar concentrations,
and do not induce expression of NOS, sGC, or HO-1 [21].
Recently, we have also discovered that replacing the imidazole by
triazole or tetrazole greatly decreases the ability of this series of
compounds to inhibit the cytochrome P450 family of drug
metabolizing enzymes [22]. We have been successful in identifying
several compounds as potent and selective inhibitors of HO-1
[21,23–27]. Preliminary data show some of these compounds to be
able to attenuate the tumour size and metastases of breast cancer
cells (Dercho et al., unpublished results). Moreover, several of our
compounds are already being used by other research groups as tools
to dissect HO function [28].
As part of our program to ‘‘build a better inhibitor’’ we have
complemented functional analyses with structural studies of
complexes formed between human HO-1 and various QC-xx
complexes (Figure 2) using X-ray crystallography (reviewed in
[29]). We have successfully crystallized complexes with 1-
(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone (QC-82) [30], 4-
phenyl-1-(1,2,4-1H-triazol-1-yl)-2-butanone (QC-86) [27], and
(2R,4 S)-2-[2-(4-chlorophenyl)ethyl]-2-[(1H-imidazol-1-yl)methyl]-
4-[((5-trifluoromethylpyridin-2-yl)thio)methyl]-1,3-dioxolane (QC-
80) [31]. These structures, in addition to that of 2-[2-(4-
chlorophenyl)ethyl]-2-[1H-imidazol-1-yl)methyl]-1,3-dioxolane (QC-
15) with rat HO-1 [32], have enabled the identification of key
features required for binding to hHO-1 as well as the mechanism
underlying its inhibition, and insights toward the design of more
effective inhibitors. In general, these azole-based inhibitors exhibit a
common binding and inhibition mode. The azole moiety in the
eastern region serves as an anchor which coordinates with the iron
atom through nitrogen 3 to form a hexacoordinate heme.
Replacement of imidazole with a triazole anchor may provide
additional stability by the formation of a hydrogen bond between
the additional nitrogen atom and the protein’s distal helix. The
linker in the central region attaches this anchor to a hydrophobic
group in the western region which fits into a hydrophobic pocket in
the distal region of the heme-binding pocket. While hydrophobic
and stacking interactions contribute to the stability of this region,
halogenationis also accommodatedin this western regionputatively
due to the presence of Met34 in the pocket or, alternatively, greater
and more points of contact within the pocket. The distal helix of the
enzyme has an inherent flexibility which allows for a range of bulky
functional groups without displacing the heme moiety or the
catalytically critical Asp140. The proximal helix was also found to
have some degree of flexibility; interaction of QC-80, containing a
large northeastern substituent, induces a conformational change to
‘‘unkink and extend’’ the helix and induce the formation of a
peripheral hydrophobic pocket to accommodate this group. As a
result, binding of the QC-xx inhibitors to the distal side of the heme
binding pocket results in the disruption of an ordered hydrogen
bond network involving Asp140 and displacement of a catalytically
critical water molecule, to inhibit heme oxidation.
Previously, one of our crystal structures of inhibitor-complexed
hHO-1 revealed a putative, proximal secondary hydrophobic
pocket not apparent in other complex or native structures [30]. To
Figure 1. The oxidative degradation of heme in the carbon
monoxide/heme oxygenase (CO/HO) pathway.
doi:10.1371/journal.pone.0029514.g001
Figure 2. Structures of azalanstat and QC-xx compounds used for crystallization studies.
doi:10.1371/journal.pone.0029514.g002
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strategy to create compounds which would occupy both
hydrophobic pockets simultaneously in order to increase potency.
Thus, we have synthesized and characterized 1-(1H-imidazol-1-
yl)-4,4-diphenyl-2-butanone (QC-308), the diphenyl analogue of
one of our most potent inhibitors, (4-phenyl-1-(1H-imidazol-1-yl)-
2-butanone (QC-65;I C 50=4.061.8 mM) [23], which contains an
additional phenyl group in the western region of the compound, in
contrast to the usual single hydrophobic moiety found in most of
this series (Figure 3). Notably, since QC-65 is already one of the
most potent inhibitors, further improvement in potency was very
challenging and required a new strategy such as the one exploited
to create QC-308. The X-ray crystal structure of the inhibitor-
hHO-1 complex definitively demonstrates the presence of a
secondary hydrophobic pocket which acts to stabilize the second
phenyl moiety of this structure in addition to the distal
hydrophobic pocket common to previous structures. As a result,
the two phenyl moieties each fit into separate hydrophobic
pockets. This ‘‘double-clamp’’ binding mode, thus, most likely
accounts for the increased potency of this inhibitor by providing
additional stabilization, thereby providing for improvement of
human heme oxygenase inhibitors.
Results and Discussion
Synthesis and Functional Characterization of QC-308
In this study, we report the synthesis and characterization of 1-
(1H-imidazol-1-yl)-4,4-diphenyl-2-butanone (QC-308), the diphe-
nyl analogue of one of our most potent HO inhibitors, QC-65
[23]. The synthesis involved bromination of commercially
available 4,4-diphenyl-2-butanone to afford 1-bromo-4,4-diphe-
nyl-2-butanone, followed by nucleophilic displacement of the
bromo group by imidazole to give 1-(1H-imidazol-1-yl)-4,4-
diphenyl-2-butanone and conversion into its hydrochloride QC-
308. One of our initial crystal structures of inhibitor-complexed
hHO-1 revealed a putative, secondary hydrophobic pocket
proximal to the distal pocket, not observed in other native or
complexed structures [30]. In that previous analysis, it was
suggested that this secondary pocket was induced upon binding of
inhibitor as it was not apparent in the high resolution native
structure. At the time, it was postulated that it may accommodate
the bulky group in the thio-(4-aminophenyl) region of azalanstat
which we later refuted by the observation of the inducible binding
mode of hHO-1 with QC-80 [31]. Thus, to exploit this putative
interaction, we modified our strategy and QC-308 was designed
to contain two phenyl groups which would occupy both
hydrophobic pockets simultaneously (Figure 3). Initial screening
of QC-308 using a CO formation assay with rat spleen
microsomal fractions gave an IC50 of 0.2760.07 mM (Figure 4),
,15-fold more potent than its monophenyl analogue
(IC50=4.061.8 mM, [23]).
Binding of QC-308 to the truncated, recombinant hHO-1
protein used for crystallization was also assessed spectrally. As seen
with our previous azole-based inhibitors [30,33], in the absence of
inhibitor, the heme-bound hHO-1 showed a characteristic
spectrum witha Soret peak of 404 nm.In the presence of increasing
amounts of inhibitor (1–25 mM), the peak was red-shifted up to
410 nm with a more prominent shoulder centred at 355 nm
(Figure 5A). The increases in secondary peaks at 535 and 560 nm
with a decrease at 630 nm were also similar to what was previously
observed with this type of inhibitor [30], thus implying a change in
the heme environment and putative binding of the inhibitor. Heme
degradation in the presence of increasing amounts of inhibitor was
initiated by the addition of L-ascorbic acid, and followed for
90 minutes. Heme absorbance was half-maximal by 11–12 minutes
in the absence of inhibitor, which was retarded with increasing
amounts of QC-308 (Figure 5B). Initial rates were determined for
each condition by calculating the rate of change of absorbance over
the initial linear portion of the graph (between 2–3 min), according
to its respective Soret peak. At a concentration of 25 mM the Soret
peak had shifted to 410 nm, and the initial rate had decreased to
9.860.5% of the control (Figure 5C). A full spectral analysis was
also performed after the 90 minutes to measure the attenuation of
heme degradation by QC-308. With increasing amounts of
inhibitor, there was a concomitant increase in the height of the
Soret peak indicating the amount of intact heme remaining; at
25 mM, 71.663.0% of the original heme was undegraded cf.
31.160.3% for the control (Figure 5D).
There appears to be a discrepancy in the potency of this
compound between the CO formation assay on spleen microsomes
and the optical assay with recombinant protein. Notably, the
initial rate was decreased to ,50% by 10 mM i.e. a 1:1
enzyme:inhibitor molar ratio which is much higher than the
IC50 (0.27 mM) determined with the microsomal preparation.
Indeed,thisdiscrepancywas observed inpreviousstudiescomparing
Figure 3. Structure of 1-(1H-imidazol-1-yl)-4,4-diphenyl-2-bu-
tanone (QC-308). QC-65 lacks the second phenyl moiety.
doi:10.1371/journal.pone.0029514.g003
Figure 4. Inhibition of HO-1 activity by QC-308. Enzyme activity
was determined by measuring the CO produced in 15 min from 50 mM
methemalbumin using 0.5 mg/mL rat spleen microsomes. The IC50 was
determined by nonlinear regression using GraphPad Prism version 4.
Curves represent two independent trials, with each performed in
duplicate.
doi:10.1371/journal.pone.0029514.g004
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hHO-1 which revealed that the longer, native form of HO-1 was
more susceptible to inhibition than the truncated form [34].
Crystallization and Structure Determination of hHO-1 in
Complex with QC-308
Similar to previous co-crystallization studies with the azole-
based HO-inhibitors, binding of QC-308 to hHO-1 was
confirmed prior to setting up co-crystallization trials by spectral
analyses. Protein was incubated with QC-308 at a 1:3 molar ratio,
respectively, resulting in a shift in the Soret peak from 404 nm to
410 nm, similar to what had been observed previously [30,31],
thus verifying binding. Co-crystallization trials were based on
previous conditions and resulted in crystals very similar to those
obtained previously from both native and hHO-1 in complex with
the previous azole-based inhibitors. Diffraction data were obtained
to a resolution of 2.85 A ˚. In contrast to previous native [35–37]
and complex structures of hHO-1 [26,27,29–31], the data were
Figure 5. Spectral analysis of QC-308 binding to hHO-1. (A) Heme-conjugated hHO-1 (10 mM) in 20 mM potassium phosphate (pH 7.4) was
incubated with increasing concentrations of QC-308 at room temperature. Absorbances were measured over a range of 300-700 nm at intervals of
1 nm, and values were corrected for buffer (20 mM potassium phosphate, pH 7.4). The assays were performed in duplicate and the values averaged.
The Soret peak gradually shifted from 404 to 410 nm with increasing concentrations of QC-308. Secondary peaks centered at 535 and 560 nm were
amplified with increasing concentrations of inhibitor, while a third minor peak at 630 nm decreased until no longer detectable at high inhibitor
concentrations (B) Heme degradation rates in the presence of QC-308. Heme degradation was subsequently initiated by the addition of 1 mM L-
ascorbic acid and allowed to proceed for 90 min at room temperature. Absorbances were measured at 404, 406, 408 and 410 nm at 1 min intervals
and normalized to the initial absorbance (t=0) for the respective condition. Graph is representative of one replicate for each condition at the
wavelength of its Soret peak (indicated in legend). (C) Initial rates were determined for each condition over a period of 1 min (from t=2–3 min) at the
wavelength corresponding to its respective Soret peak as indicated in the legend in (B). For each replicate, values were normalized to the respective
control condition, and subsequently averaged. Parallel reactions were also performed for heme-conjugated hHO-1 in the absence of both inhibitor
and electron donor (L-ascorbic acid) as a negative control (i.e., no oxidative degradation). (D) Spectral analysis following heme degradation.
Absorbances were measured and analyzed as described in (A). Heme degradation corresponded to the disappearance of the Soret peak. Increasing
concentrations of inhibitor resulted in increased attenuation of the loss of the Soret peak as well as of the secondary peaks at 535 and 560 nm but
the appearance of a peak at 699 nm. Inset depicts the fraction of heme still undegraded after the 90 min reaction, relative to that present at t=0 for
each condition.
doi:10.1371/journal.pone.0029514.g005
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dimensions. Interestingly, this is similar to that found for the
hHO-2 crystal structure [38]. Molecular replacement was carried
out as previously described using the native heme-conjugated
hHO-1 complex (PDB code 1N3U, A chain) as the initial probe.
Two unambiguous solutions, corresponding to the two molecules
in the asymmetric unit, were obtained (LLG=2315) and the
position of the inhibitor was clear from the resultant Fo-Fc map
following initial refinement. The structure was refined to an R of
0.223 and Rfree of 0.264. A total of 26 water molecules were added
to the structure as well as one molecule of 1,6-hexanediol (Figure
S1). The Ramachandran plot demonstrated no residues in the
disallowed region. Diffraction and final refinement statistics are
given in Table 1.
The two molecules in the asymmetric unit (A and B) were
virtually superimposable with a Ca RMSD of 0.391 A ˚ (upon
alignment of all atoms). The greatest discrepancy was observed in
the distal helix (Gly144: 1.286 A ˚) (Figure S2), which is not
surprising given its inherent flexibility [35]. Density corresponding
to a molecule of 1,6-hexanediol was also only observed in molecule
A. The position of this molecule was remote from the inhibitor
binding site and was, thus, deemed irrelevant to the protein’s
interaction with QC-308. In general, the density associated with
molecule A was more disordered and less complete than that
associated with molecule B. As such, all further analyses will be
focused on molecule B.
The overall structure of hHO-1 in complex with QC-308 was
similar to previous structures determined for the protein with the
azole-based inhibitors, generally following the common binding
mode already established for most of this type of inhibitor
(reviewed in [29]). In brief, the inhibitor binds to the distal side of
heme in the heme-binding pocket with the imidazolyl group
serving as the sixth ligand of coordination with the heme iron i.e.
the anchor for the binding (Fe–imidazolyl distance=2.1 A ˚)
(Figure 6A). The western region of the inhibitor fits into the
hydrophobic pocket which extends back towards the distal side of
the heme binding pocket with the distal helix shifting outward to
accommodate this region. Alignment with the ‘‘closed’’, more
active, form of the native holoenzyme (PDB Code #1N45) shows
a maximal shift outward of 2.349 A ˚ (Gln145) in this distal helix.
Interestingly, the distal helix does not shift as much as was
observed in binding the QC-82 compound (PDB Code # 3CZY)
which contains the bulky adamantanyl substitutent in the western
region, despite the larger area taken up by the diphenyl moiety;
the Gly144 residue is shifted 2.972 A ˚ further with QC-82 than the
current complex structure. Moreover, comparison with the
complex of hHO-1 with QC-80, which contains a bulky
substituent in the northeastern region, indicated that the induced
shift of the proximal helix observed in that complex resulting in a
novel, proximal hydrophobic pocket to accommodate the bulky 5-
trifluoromethylpyridin-2-yl group [31] is also not necessary (Figure
S2). In fact, the QC-308 compound seems to ‘‘slide’’ easily into its
binding site with relatively little conformational change to the
native structure.
Examination of the electrostatic surface representation of the
hHO-1–QC-308 structure shows the presence of the distal
hydrophobic pocket which accommodates one of the two phenyl
groups (Figure 6B). Moreover, the second phenyl moiety fits
comfortably into a secondary proximal hydrophobic pocket, very
similar to but larger than that observed previously. Analysis of the
protein residues within van der Waals distance of the inhibitor
(Table S1) indicates that metal coordination and hydrophobic
interactions stabilize its binding. No hydrogen bond networks,
seen to be involved in the stabilization of some previous
compounds, were apparent in this structure. Thus, it appears that
the two hydrophobic pockets serve as a ‘‘double-clamp’’ to
stabilize the two phenyl groups in the western region of this
compound and increase the stability of the complex, making for a
more potent inhibitor than those previously designed.
Isozyme-selectivity of QC-308
The QC-308 compound was also screened for inhibitory
activity against HO-2 using rat brain microsomal fractions. Using
the CO formation assay, an IC50 of 0.4660.15 mM was obtained
(Figure 7), comparable to that of HO-1. Parallel experiments were
also performed using a recombinant hHO-2 truncation derivative
(1–264 amino acids with an N-terminal His–tag) to allow
comparison with the hHO-1 truncated protein (Figure 8).
Interestingly, the spectral changes upon addition of QC-308 were
similar to those seen for hHO-1, implying a similar change in the
heme environment (Figure 8A). It should be noted that, in this
Table 1. Diffraction and refinement statistics
a.
Space group P212121
a (A ˚) 54.61
b (A ˚) 74.98
c (A ˚) 115.28
b (u) 90.000
Molecules in the asymmetric unit 2
Solvent content (%) 41.65
Mosaicity (u) 0.51
Resolution range (A ˚) 20–2.85
Total reflections 48116 (2557)
Unique reflections 11070 (570)
Completeness (%) 95.6% (96.9%)
I/s 20.81 (3.82)
bRmerge 7.2% (56.1%)
Average redundancy 4.35 (4.46)
Refinement statistics
Sigma cutoff for refinement None
cRcrys 0.22312
cRfree 0.26377
Number of reflections used 10516
Number of reflections in test set 554
Number of non-hydrogen atoms
used in refinement
3662
RMSD bond lengths (A ˚) 0.006
RMSD bond angles (u) 0.910
Number of water molecules 26
Ramachandran Plot
Most favoured (%) 93.3
Additional allowed (%) 6.7
Generously allowed (%) 0.0
Disallowed regions (%) 0.0
aValues in parentheses are for the outermost shell (2.91-2.85 A ˚).
bRmerge=S|Iobs2,I.|/SIobs, where Iobs is the intensity measurement and ,I.
is the mean intensity for multiply recorded reflections.
cRcryst and Rfree=S|Fobs2Fcalc|/S|Fobs| for reflections in the working and test
sets, respectively.
doi:10.1371/journal.pone.0029514.t001
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(0.01360.012 pmol CO/min) was found to be less than that of
hHO-1 (0.06060.002 pmol CO/min), as observed by the
shallower curves; heme absorbance was half-maximal by 42–
44 minutes (cf. 11–12 minutes for hHO-1) (Figure 8B). Increasing
the inhibitor concentration also attenuated the degradation of
heme as observed by the heights of the Soret peaks measured after
the reaction; 25 mMo fQC-308 resulted in 87.261.9% of the
original heme still undegraded cf. 32.860.7% for the control.
Interestingly, the potency of inhibition with this truncation
derivative is also discrepant relative to the CO formation assay.
It should be noted that in our previous comparisons of native
versus recombinant HO-2, the results were more comparable.
However, the recombinant protein used in that study was a GST-
fusion derivative which also contained a Cys127Ala mutation
which disrupts HRM3, one of HO-2’s heme regulatory motifs
(HRMs).
Previous analyses of QC-65 had revealed IC50 values of
4.061.8 mM and 11.364.7 mM against HO-1 and HO-2,
respectively, using the CO formation assay with rat spleen and
brain microsomes [23]. Isoselectivity was seen when the central
ketone group of QC-65 was changed to a dioxolane (QC-57; 2-[2-
phenylethyl]-2-[(1H-imidazol-1-yl)methyl]1,3-dioxolane) with IC50’s
of 0.760.4 mM and .100 mM for HO-1 and HO-2, respectively
[23]. It would be interesting to see if a diphenyl analogue of this
compound could further improve potency while maintaining
isoselectivity.
In order to try and determine the basis of isoselectivity, we
turned again to structural analyses. The crystal structure of a
truncated derivative of hHO-2 (1–264; Cys127Ala) has been
determined (PDB Code #2QPP) [38]. Alignment of this structure
of the native hHO-2 holoenzyme with that of the hHO-1–QC-
308 complex confirmed that the catalytic cores of these two
enzymes are structurally conserved [38] with an RMSD of
0.874 A ˚ over the 202 aa alignment length. Closer inspection of the
residues involved in QC-308 interaction in hHO-1 showed no
significant changes in hHO-2 which may account for the isozyme-
selective behaviour (Figure 9) seen when the ketone is changed to a
dixolane group. Indeed, of the contact residues, only four
differences were seen between the two isozymes: Phe167Tyr,
Val50Ala, Met34Val, and Leu213Ile. The Cys127 residue
comprising HRM3 (mutated to Ala in the HO-2 structure) is
Figure 6. Crystal structure of heme–conjugated hHO-1 in complex with QC-308 at 2.85 A ˚ resolution. (A) Ribbon diagram of the inhibitor
binding site. Heme (orange) and QC-308 (yellow) are depicted as stick models. An omit map (Fo-Fc) contoured at 2s is superimposed. Dashed lines
indicate coordination of imidazole nitrogens of QC-308 and His25 with the heme Fe. Residues involved in inhibitor binding are indicated. (B)
Electrostatic surface potentials revealing the presence of two distal hydrophobic pockets (1u HP and 2u HP) which accommodate the two phenyl
groups of QC-308: a ‘‘double-clamp’’. Dashes indicate coordination of the imidazole group with the heme Fe. Blue and red colours indicate positive
and negative electrostatic potentials, respectively, as calculated using PyMOL [60].
doi:10.1371/journal.pone.0029514.g006
Figure 7. Inhibition of HO-2 activity by QC-308. Enzyme activity
was determined by measuring the CO produced in 15 min from 50 mM
methemalbumin using 0.5 mg/mL rat brain microsomes. Calculations
were performed as described for Figure 4.
doi:10.1371/journal.pone.0029514.g007
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may not be involved in attributing selectivity on its own.
Moreover, it is not immediately apparent as to why the two
recombinant proteins would have such different catalytic rates in
the optical assay.
The greatest sequence divergence between HO-1 and HO-2 lies
within the C-terminal domain which contains a membrane-
binding domain, with a second region around Cys127 in HO-2
(i.e. HRM3) [38]. Studies comparing recombinant full-length HO-
1 protein and a soluble 30 aa truncated protein indicated that the
C-terminal 23 amino acids are essential for maximal activity (2–
56when measuring bilirubin formation) [39,40]. The C-terminal
domain is thought to mediate the formation of a high-affinity
complex with cytochrome P-450 reductase, as well as, membrane
incorporation, thus resulting in increased activity [41]. The C-
terminus seems to have a regulatory role in both of these isozymes.
In HO-1, cleavage of 52 aa at the C-terminus affects nuclear
import, leading to activation of genes associated with protection
against oxidative stress [42]. In HO-2, heme regulatory motifs
(HRM1 and HRM2) are located in this region and act as a thiol/
disulfide redox switch to modulate heme affinity depending on the
oxidation state of the environment. Early studies suggested that
these HRMs are additional heme binding motifs [43–45].
However, more recent studies have shown that the HRMs affect
the heme Kd, but not the kcat for heme degradation, without
binding additional heme moieties [46,47]. Moreover, spectral
studies suggest Cys265 of HRM1 competes with His45 as an axial
ligand to ferric heme bound to HO-2 under reducing conditions
[48]. Unfortunately, the crystal structures of both human HO-1
and HO-2 are of truncated proteins which lack this region.
Furthermore, in the HO-2 structure, both the membrane binding
domain and two heme regulatory motifs (HRM1 and HRM2) are
missing while HRM3 has been removed by a Cys127Ala mutation
[38]. Thus, structural information regarding the full-length
isozymes will be crucial in elucidating isoselectivity of the QC-
xx compounds as well the basis behind the lack of selectivity for
QC-308 and QC-65, as opposed to QC-57.
Conclusions
The binding of QC-308 to hHO-1 reveals a novel ‘‘double-
clamp’’ binding mode. The presence of a secondary hydrophobic
pocket provides an additional site of stabilization for the second
Figure 8. Spectral analysis of QC-308 binding to hHO-2. Analyses were done in parallel to those in Figure 5.
doi:10.1371/journal.pone.0029514.g008
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,15-fold increase in potency for this inhibitor. This information
may be utilized as a basis to modify isozyme-selective inhibitors to
increase potency while maintaining isoselectivity. It is clear,
however, that structural information regarding the full-length
isozymes will be crucial in elucidating isoselectivity of the QC-xx
compounds.
Materials and Methods
Ethics Statement
All animals were cared for in accordance with the principles and
guidelines of the Canadian Council on Animal Care, and
experimental protocols were approved by the Queen’s University
Animal Care Committee.
Synthesis of QC-308
General. Flashcolumn chromatography was performed on
Silicycle silica gel (230–400 mesh, 60 A ˚). Analytical thin-layer
chromatography was performed on glass-backed pre-coated Silica
Gel 60 F254 plates (Silicycle), and the compounds were visualized
by UV illumination (254 nm). Melting points were measured on a
Mel-Temp II apparatus and are uncorrected.
1H and
13C NMR
spectra were recorded on a Bruker Avance 400 spectrometer in
CDCl3 or CD3OD. The chemical shifts are reported in d (ppm)
relative to tetramethylsilane [49]. The compounds synthesized
were deemed .95% pure by
1H NMR analysis. High-resolution
ESI mass spectra were recorded on an Applied Biosystems/MDS
Sciex QSTAR XL mass spectrometer with an Agilent HP1100
Cap-LC system. Samples were run in 50% aqueous MeOH at a
flow rate of 6 mL/min. High-resolution EI mass spectra were
recorded on a Waters/Micromass GC-TOF instrument.
Preparation of 1-bromo-4,4-diphenyl-2-butanone. (4,4-
Diphenyl-2-butanone was obtained from Alfa Aesar, Ward Hill,
MA, USA.) Under an atmosphere of nitrogen, 4,4-diphenyl-2-
butanone (1248 mg, 5.56 mmol, 1 equiv) was dissolved in
methanol (10 mL) and a solution of bromine (0.29 mL, 889 mg,
5.56 mmol, 1 equiv) in methanol (7 mL) was added dropwise at
RT. The mixture was stirred at RT for 6 h, an aqueous solution of
sodium thiosulfate (0.3 M, 10 mL) was added, and the mixture
concentrated. To the residue was added brine, and the mixture
extracted with ethyl acetate (36). The combined organic extracts
were washed with brine (26), dried over sodium sulfate, then
concentrated. High-vacuum drying left the crude product
(1745 mg) as a brown oil;
1H NMR (400 MHz, CDCl3): d 3.43
(d, J=7.6 Hz, 2H), 3.75 (s, 2H), 4.63 (s, 1H), in addition to signals
attributed to starting material and the 3-bromo isomer;
13C NMR
(100 MHz, CDCl3): d 34.8, 46.0, 46.3, 126.8, 127.8, 128.8, 143.4,
200.3; HRMS (EI) [M]
+ Calculated for C16H15BrO: 302.0306.
Found: 302.0286.
1-(1H-Imidazol-1-yl)-4,4-diphenyl-2-butanone hydrochloride
(QC-308). Under an atmosphere of nitrogen, a sample of the
crude 1-bromo-4,4-diphenyl-2-butanone (836 mg, 2.76 mmol, 1
equiv) was dissolved in N,N-dimethylformamide (11 mL) and to
this solution was added imidazole (752 mg, 11.05 mmol, 4
equiv) at RT. The mixture was stirred at 80uC for 24 h, then
cooled to RT. Water was added and the mixture extracted with
ethyl acetate. The organic extract was washed sequentially with
a solution of sodium bicarbonate in brine (36), and brine, dried
over sodium sulfate, then concentrated. The residue was
purified by flash column chromatography on silica gel (ethyl
acetate as eluent, product Rf ,0.2) to give the free base
(144 mg, 0.50 mmol, 18%). To a solution of the free base in
warm 2-propanol (2 mL) was added a solution of 37% aqueous
HCl (60 mg, 0.61 mmol, 1.2 equiv) in 2-propanol (2 mL). The
mixture was concentrated and dried under high vacuum,
leaving the product (151 mg, 0.46 mmol, 17%) as a beige
solid; mp 218–220uC;
1H NMR (400 MHz, CD3OD): d 3.48 (d,
J=7.6 Hz, 2H), 4.61 (t, J=7.4 Hz, 1H), 5.27 (s, 2H), 7.16–7.20
(m, 2H), 7.24–7.34 (m, 9H), 7.52 (s, 1H), 8.75 (s, 1H);
13C
NMR (100 MHz, CD3OD): d 46.5, 46.9, 58.3, 120.5, 124.5,
127.6, 128.8, 129.7, 137.6, 145.1, 201.1; HRMS (ESI) [M-Cl]
+
Calculated for C19H19N2O: 291.1497. Found: 291.1490.
HO Activity Assay. HO activity in rat spleen and
microsomal fractions was determined by quantifying the CO
formed from the degradation of methemalbumin (heme
complexed with albumin) [50,51] as described previously [30].
Expression and Purification of hHO-1 and hHO-2. A
truncated, soluble version of hHO-1 containing 233 amino acids
(hHO1-t233) was previously utilized successfully to solve the high-
resolution crystal structure of native hHO-1 [35–37] as well as
hHO-1 in complex with imidazole-based inhibitors [26,27,30,31].
The hHO1-t233/pBAce expression plasmid was a generous gift
from Dr. Ortiz de Montellano (University of San Francisco).
Bacterial expression and purification of hHO-1 from DH5a cells,
and subsequent heme conjugation, were performed as described
previously [30], based on published protocols.
A truncated, soluble version of hHO-2 containing 264 amino
acids was utilized for comparison studies with hHO1-t233. The
hHO-2(1-264)/pET28a expression plasmid was a generous gift
from Dr. Stephen Ragsdale (University of Michigan). The
expressed protein contained an N-terminal histidine tag to allow
purification by metal chelation. Briefly, BL21 (DE3) cells,
transformed with the hHO-2(1–264)/pET28a plasmid, were
Figure 9. Ribbon diagram showing the structural alignment of
hHO-2 (cyan) with the hHO-1–QC-308 complex (green). Residues
involved in QC-308 binding are depicted as stick models, as are heme
and QC-308 (yellow). The two structures are virtually identical in this
catalytic core. Residues of hHO-2 which differ amongst the contact
residues of the hHO-1 inhibitor binding site are depicted in red.
Structural alignments were performed using ‘‘Superpose’’ in CCP4
[54,58].
doi:10.1371/journal.pone.0029514.g009
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37uC following inoculation from a miniculture. After reaching an
OD600of,0.8,proteinexpressionwasinducedwith1 mMIPTGin
the presence of 50 mg 5-aminolevulinic acid hydrochloride (Sigma)
(thelatterwaslaterdeemedunnecessary).Cellswereallowedtogrow
for a further 3–4 hours at 37uC before harvesting by centrifugation.
Cell pellets were stored at 280uC until ready for use. Pellets were
subsequently thawed on ice, resuspended in lysis buffer [50 mM
NaH2PO4 (pH 8.0), 300 mM NaCl, 3 mM imidazole, lysozyme
(0.5 mg/mL; BioShop), DNAseI (5 units/mL; Fermentas) EDTA-
free protease inhibitor cocktail (1 tablet/50 mL; Roche)] and
incubated on ice for 30 min with rocking, followed by sonication.
Lysates were cleared by centrifugation and the supernatant
incubated with Ni-NTA agarose resin, which had been equilibrated
with 50 mM NaH2PO4 containing 300 mM KCl, for 1 hour at
4uC. Subsequently, the resin was poured into a column for
purification. Unbound protein was washed with buffer containing
15 mM imidazole, followed by a gradient from 20–200 mM
imidazole; the protein eluted with 500 mM imidazole. Protein-
containing fractions were visualized by 12% SDS-PAGE, pooled
and dialyzed against 50 mM Tris pH 7.5, 100 mM KCl. The apo
protein concentration was determined using the Bradford method
(BioRad). A stock hemin (Fluka) solution (8 mg/mL) was prepared
by dissolving 12 mg into 170 mL of 10% ethanolamine, followed by
dilution into 50 mM Tris (pH 7.5), 100 mM KCl. The hemin
solution was slowly added to the apo hHO-2 protein preparation to
a finalmolarratio of2:1,rocked at 4uC for20–30 min,and stored at
220uC. Subsequently, excess heme was removed by passage over a
PD-10 size-exclusion column(Amersham Biosciences)that had been
equilibrated with 50 mM Tris (pH 7.5), 100 mM KCl. Protein
concentration was determined by absorbance (e405) 171.46
1.2 mM
21 cm
21) [46]. Purity was assessed by measurement of the
Rz ratio (A405/A280.2.1) and by SDS-PAGE analysis.
Spectral Analysis. Inhibitor binding and heme degradation
assays were performed on recombinant hHO proteins by
measuring absorbance using a microplate spectrophotometer
(Bio-Tek Instruments) as described previously [30,33]. Briefly,
inhibitor binding was determined by incubation of 10 mM heme-
conjugated hHO-1 with increasing concentrations of QC-308 (0–
25 mM) in 20 mM potassium phosphate buffer. Spectra were
recorded between 300 and 700 nm at 1 nm intervals. After the
determination of the Soret peak position at each inhibitor
concentration, heme degradation was initiated by the addition of
L-ascorbic acid to a final concentration of 1 mM and followed by
measuring absorbance at the wavelength corresponding to the
respective Soret peaks at 1 min intervals for a period of 90 min.
Initial rates of decrease of the Soret band were calculated at the
wavelengths of the respective Soret peaks. Spectra were measured
from 300 to 700 nm following the reaction period.
Crystallization. Crystallization was performed using sitting-
drop vapour diffusion as described previously [30], based on
published protocols [35–37]. The crystallization conditions
consisted 100 mM HEPES (pH 7.5), 2.2 M ammonium sulfate
0.95% 1,6-hexanediol. The heme–hHO-1 complex (412 mMi n
20 mM potassium phosphate) was mixed with QC-308 at a molar
ratio of 1:3 and binding was confirmed using spectral analysis to
confirm a shift in the native Soret peak (from 404 nm to 410 nm)
prior to setting up crystallization plates, as described previously
[30]. Crystallization drops consisted of 2 mL of the protein-
inhibitor solution mixed with 2 mL of the reservoir solution.
Data Collection and Structure Determination. X-ray
diffraction measurements were performed at the Advanced
Photon Source (APS) at Argonne National Laboratory (Chicago,
Illinois) at the 23-ID-D beamline. For data collection, a
cryoprotectant comprising 100 mM HEPES pH 7.5, 2.32 M
ammonium sulfate, 1% 1,6-hexanediol, 20% glycerol was used.
Crystals were subsequently flash-cooled in a stream of N2 at 100 K.
Data were collected for 360u with an oscillation of 0.5u and 240
frames processed using XDS for structure determination [52]. The
structure of the protein-inhibitor complex was solved by molecular
replacement (MR) using Phaser [53] in the CCP4 suite [54]. The
heme-hHO-1 complex (PDB code 1N3U, Chain A) was the initial
probe. An initial template of QC-308 was generated using the
Dundee PRODRG2 server [55], and the library files created using
Monomer Sketcher in the CCP4 suite. Following initial refinement
with Refmac in the CCP4 suite, the structure of the inhibitor was
inserted and subsequently refined using iterative cycles of Coot [56]
and Refmac5 [57] in the CCP4 suite. Standard parameters for
heme were used as described in its library entry in the program
during refinement, with no additional restraints on planarity, bond
lengths, and bond angles. Structural alignments were performed
using Superpose [58] in CCP4. Contacts were calculated using
Contacts in CCP4. Ramachandran plots were determined using
PROCHECK in CCP4 [59]. Electrostatic surface potentials were
calculated and all images were prepared using PyMOL [60].
Supporting Information
Figure S1 Structure of heme-conjugated hHO-1 in
complex with 1-(1H-imidazol-1-yl)-4,4-diphenyl-2-buta-
none (QC-308) at 2.85 A ˚ resolution. Ribbon diagram of the
two molecules in the asymmetric unit. Heme (orange) and QC-
308 (yellow) are depicted as stick models, as is the molecule of 1,6-
hexanediol (magenta). Image was created in PyMol [60].
(TIF)
Figure S2 Structural alignment. Top: Plot of the RMS
deviation of main chain backbone atoms of the A and B molecules
of hHO-1 in complex with QC-308. Bottom: Alignment of the B
molecule with the native holoenzyme (PDB code 1N45, Chain-A),
hHO-1 in complex with QC-82 (PDB code 3CZY, Chain-A), and
hHO-1 in complex with QC-80 (PDB code 3HOK, Chain B).
Structural alignments were performed using ‘‘Superpose’’ in
CCP4 [54,58].
(DOC)
Table S1 Contacts between heme-conjugated hHO-1
and 1-(1H-imidazol-1-yl)-4,4-diphenyl-2-butanone. Resi-
dues #4.0 A ˚ apart are listed. Atom names of inhibitor refer to
nomenclature in the PDB. Distances were calculated using
‘‘Contacts’’ in CCP4 [54].
(DOC)
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